MPI agent market down overall, but Cardiolite outsells Myoview

Arlington Medical Resources (AMR), which provides market data for the pharmaceutical and diagnostic imaging industries, has reported that Lantheus Medical Imaging’s Cardiolite had 15 percent more market share than GE Healthcare’s Myoview for September.

Both Cardiolite and Myoview are administered intravenously as part of a myocardial perfusion imaging (MPI) stress test to highlight areas of the heart to help diagnose coronary artery disease.

“Compared to data from our September 2007 audit, Cardiolite use has dropped nine percent. Even so, Cardiolite continues to dominate the radiopharmaceutical market,” according to Anna Fisher, analyst at AMR.

The report also found that the number of patients who were administered Astellas Pharma’s Lexiscan (regadenoson) increased 58.5 percent from August to September. Lexiscan is the newest pharmacologic stress agent on the market—introduced in June—and it is used in patients unable to undergo exercise stress testing.

AMR said its report is a syndicated audit, available monthly, designed to track the number of nuclear myocardial perfusion tests performed in hospital and non-hospital settings. 

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup